ClinicalTrials.gg
Active, not recruitingNCT05740176Updated Nov 2, 2026

The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery

An interventional study of Anterior Cervical Discectomy and Fusion in Cervical Degenerative Disc Disease, sponsored by Synergy Spine Solutions. Active, not recruiting at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Synergy Spine Solutions · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Primary completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Planned enrollment
28th of 141
200 · median 57
Started
2023
with 7 others
No phase
90 of 232
15 open now
Primary completion
2026-11
later than 22 of 57 live
Registered
203rd of 232
by date

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 28th largest by planned enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2023, is one of 90 with no phase, reaches primary completion later than 22 of the 57 other live ones, and was the 203rd registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

A multicenter, prospective, non-randomized, historically controlled study. To demonstrate the Synergy Disc is at least as safe and effective as conventional anterior cervical discectomy and fusion (ACDF) to treat cervical degenerative disc disease (DDD) in subjects who are symptomatic at two levels from C3 to C7 are and are unresponsive to conservative management. Patients will be evaluated preoperatively, at the time of surgery, and at 6 weeks, and 3, 6, 12, and 24 months after surgery. Follow-up will continue annually until the last patient reaches 24-month follow-up. The primary analysis will occur at 24 months.

Read the detailed description

This is a research study comparing two ways of treating neck problems caused by degenerative disc disease (wear-and-tear damage to the discs that cushion the bones in the neck).

The study is comparing:

The Synergy Disc - an artificial disc device being studied in this trial, and Standard surgery (ACDF) - a widely used procedure called anterior cervical discectomy and fusion, which is the accepted current treatment.

Up to 200 people will receive the Synergy Disc as part of this study. Their results will be compared to results from people who had the standard ACDF surgery in the past, rather than assigning some people to get ACDF during this study (this is called a "historical control"). The study takes place at multiple medical centers.

Who this study is for:

People who are fully grown (skeletally mature) and have damage in two neighboring discs in the neck (located somewhere between the C3 and C7 vertebrae). To qualify, a person's symptoms must include:

Arm pain and/or nerve-related weakness or numbness (radiculopathy) that hasn't improved, and Neck pain or signs of spinal cord compression (myelopathy)

These symptoms must be caused by problems in the two affected disc levels, and must not have gotten better with non-surgical treatment (such as physical therapy, medication, or injections).

What the study will measure:

Whether the Synergy Disc is as safe and effective as standard ACDF surgery for people who need surgery to relieve pressure on the nerves or spinal cord at two neighboring disc levels in the neck.

03

Conditions studied

  • Cervical Degenerative Disc Disease

Keywords

  • degenerative disc disease
  • cervical
  • artificial disc replacement
  • motion preservation
  • motion preservation disc
  • cervical TDR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, subjects must meet all of the following criteria:

  1. Must be at least 18 years of age and be skeletally mature at the time of surgery
  2. Has a preoperative neck pain score ≥ 8 (out of 20) based on the preoperative Neck and Arm Pain Questionnaire.
  3. Has cervical degenerative disc disease at two (2) adjacent cervical levels (from C3 - C7) requiring surgical treatment and involving intractable radiculopathy, myelopathy, or both;
  4. Has a herniated disc and/or osteophyte formation at each level to be treated that is producing symptomatic nerve root and/or spinal cord compression. The condition is documented by patient history (e.g., neck pain with arm pain, functional deficit and/or neurological deficit), and the requirement for surgical treatment is evidenced by radiographic studies (e.g., CT, MRI, x-rays, etc.);
  5. Neck Disability Index (NDI) score ≥ 30/100 (raw score of ≥ 15/50);
  6. Has been unresponsive to non-operative treatment for at least six weeks or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative management; has no previous surgical intervention at the involved levels or any subsequent planned/staged surgical procedure at the involved or adjacent level(s);
  7. If a female of , patient is non-pregnant, non-nursing, and agrees not to become pregnant during the study period;
  8. Is willing to comply with the study plan and sign the Patient Form

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from participation in this study:

  1. Has a cervical spinal condition other than symptomatic cervical DDD requiring surgical treatment at the involved levels;
  2. Has documented or diagnosed cervical instability relative to adjacent segments at either level, defined by dynamic (flexion/extension) radiographs showing:

    1. Sagittal plane translation > 3.5 mm, or
    2. Sagittal plane angulation > 20°;
  3. Prior attempted or completed cervical spine surgery, except (1) laminoforaminotomy (greater than 6 months prior to scheduled surgical treatment), which includes removal of disc material necessary to perform a nerve root decompression, with less than one-third facetectomy at any level, or (2) a successful single-level anterior cervical fusion (greater than 6 months prior to scheduled surgical treatment);
  4. Has severe pathology of the facet joints of the involved vertebral bodies;
  5. Axial neck pain only (no radicular or myelopathy symptoms);
  6. Has been previously diagnosed with osteomalacia;
  7. Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation) for females or MORES for males (Male Osteoporosis Risk Estimation Score), will be used to screen patients to determine those patients who require a DXA of the hip, a bone mineral density measurement. A SCORE or MORES ≥6 requires a DXA. If DXA is required, exclusion will be defined as a DXA bone density measured T score ≤ -2.5 (The World Health Organization definition of osteoporosis). DXA scans within the last 6 months prior to surgical treatment may be used;
  8. Has presence of spinal ;
  9. Has overt or active bacterial infection, either local or systemic;
  10. Has insulin-dependent diabetes;
  11. Has chronic or acute renal failure or prior history of renal disease;
  12. Known titanium or UHMWPE allergy;
  13. Is mentally incompetent (if questionable, obtain psychiatric consult);
  14. Is a prisoner;
  15. Is pregnant ;
  16. Is currently an alcohol and/or drug abuser or currently undergoing treatment for alcohol and/or drug abuse;
  17. Is involved with current or pending litigation regarding a spinal condition;
  18. Has received drugs that may interfere with bone metabolism within two weeks prior to the planned date of spinal surgery (e.g., or methotrexate), excluding routine perioperative anti-inflammatory drugs;
  19. Has a history of an endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's Disease, renal osteodystrophy, Ehlers-Danlos Syndrome, or osteogenesis imperfecta);
  20. Has a condition that requires postoperative medications that interfere with the stability of the implant, such as steroids. This does not include low-dose aspirin for prophylactic anticoagulation and routine perioperative anti-inflammatory drugs;
  21. Has received treatment with an therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following implantation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Synergy Disc

    The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restore kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a two level discectomy for intractable radiculopathy and/or myelopathy.

    Device: Anterior Cervical Discectomy and Fusion

Interventions

  • DeviceAnterior Cervical Discectomy and Fusion

    Anterior cervical discectomy is a surgical procedure that was developed to treat damaged cervical discs by relieving pressure on the nerve roots or on the spinal cord by removing the ruptured disc. The operation is performed by reaching the cervical spine through a small incision in the front of the neck. The soft tissues of the neck are then separated allowing for the disc to be removed. Anterior cervical discectomy has proven to be a safe and effective procedure for the treatment of degenerative disc disease. The anterior approach allows direct visualization of the entire interspace and wide decompression of the anterior aspect cervical spinal cord and nerve roots. It may be undertaken in cases of multilevel disease and interbody fusion may be performed if required

    Also known as: ACDF

06

What researchers measure

Primary outcomes

  1. NDI

    ≥ 15-point improvement in NDI Score (out of 100) in subjects at 24 months compared with baseline

    Time frame: 24 month

  2. Standardized Neurological Assessment Scales

    Maintenance or improvement in neurological status (motor and sensory only) at 24 months compared to baseline

    Time frame: 24 month

  3. Secondary Surgical Intervention

    No study failure due to secondary surgical interventions (revision, removal, re-operation, supplemental fixation) at the index levels

    Time frame: 24 month

  4. Device Related Adverse Event

    Absence of major device related adverse events defined as radiographic failure, neurological failure, or failure by adverse event as adjudicated by the CEC.

    Time frame: 24 month

Secondary outcomes

  1. SF-36

    Health Survey (SF-36) at baseline and at each follow-up time-point

    Time frame: pre-operative, 6 week, 3 month, 6 month, 12 month, 24 month

  2. VAS

    Visual analogue scale (VAS) will be used to evaluate pain where a change of at least 20mm will be considered clinically significant. Neck pain as measured on a 100mm VAS at baseline and at each follow-up time-point. Left and Right arm/shoulder pain as measured on a 100mm VAS at baseline and at each follow-up time-point. Please note, this assessment will include a "Worst" to pool together the left or right arm/shoulder scores with the higher baseline score. VAS Hoarseness on a 100mm scale.

    Time frame: pre-operative, 6 week, 3 month, 6 month, 12 month, 24 month

  3. Patient Satisfaction

    Patient Satisfaction Questionnaire

    Time frame: 6 week, 3 month, 6 month, 12 month, 24 month

  4. BZ Score

    Bazaz Dysphagia Score at 24 months compared to baseline

    Time frame: 6 week, 3 month, 6 month, 12 month, 24 month

  5. Odom's Criteria

    Results at 24 months for the investigational Synergy Disc and at 24 months for the control ACDF will also be categorized by the physician according to Odom's Criteria.

    Time frame: 6 week, 3 month, 6 month, 12 month, 24 month

07

Study locations

23 sites
  • HonorHealth
    Scottsdale, Arizona 85258, United States
  • Todd Lanman, MD
    Beverly Hills, California 90210, United States
  • DOCS Health Management LLC
    Los Angeles, California 90048, United States
  • Institute of Neuro Innovation
    Santa Monica, California 91304, United States
  • Steamboat Orthopaedic and Spine Institute
    Steamboat Springs, Colorado 80487, United States
  • Brain and Spine Center of South Florida
    Delray Beach, Florida 33445, United States
  • Kennedy-White Orthopaedic Center
    Sarasota, Florida 34232, United States
  • Indiana Spine Group
    Carmel, Indiana 46032, United States
  • Orthopedics Northeast
    Fort Wayne, Indiana 46825, United States
  • Precision Spine and Orthopaedic Associates, PA
    Overland Park, Kansas 66211, United States
  • Bone and Joint Clinic of Baton Rouge
    Baton Rouge, Louisiana 70808, United States
  • Louisiana Spine Institute
    Shreveport, Louisiana 71101, United States
  • Michigan Orthopedic Surgeons
    Royal Oak, Michigan 48073, United States
  • Carolina NeuroSurgery and Spine Associates, PA
    Charlotte, North Carolina 28204, United States
  • M3 Emerging Medical Research
    Durham, North Carolina 27704, United States
  • Pinehurst Surgical Clinic
    Pinehurst, North Carolina 28374, United States
  • Summit Spine
    Portland, Oregon 97225, United States
  • Oregon Spine Care
    Tualatin, Oregon 97062, United States
  • Austin Neurosurgeons
    Austin, Texas 78746, United States
  • DFW Center for Spinal Disorders
    Fort Worth, Texas 76132, United States
  • Texas Spine Care Center
    San Antonio, Texas 78231, United States
  • The Disc Replacement Center
    West Jordan, Utah 84088, United States
  • INOVA Neurosurgery
    Fairfax, Virginia 20190, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Nov 2026, 41 months after the start.

Of 45 industry-sponsored interventional studies with no phase under Intervertebral Disc Degeneration, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 82. This study's planned 41 months is below that.

Counting every sponsor, half of 85 studies reached it within 50 months; a quarter within 27 and three quarters within 72.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2023
First posted
Feb 22, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Nov 2026was Sep 2026
CompletionEst.
Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • INOVA Neurosurgery · Fairfax, United States
Show 1 removed
  • Atlantic Brain and Spine · Reston, United States
Nov 2, 2026
Primary completion
Sep 2026→Nov 2026
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added, 1 site removed
    Show site
    • INOVA Neurosurgery · Fairfax, United States
    Show 1 removed
    • Atlantic Brain and Spine · Reston, United States
    Primary completion Sep 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05740176
Lead sponsor
Synergy Spine Solutions
Collaborators
MCRA
Responsible party
Sponsor
First posted
Feb 22, 2023
Start date
Jun 1, 2023
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Josh Butters, ME, MBA
study director · Synergy Spine Solutions

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion